CeriBell (NASDAQ:CBLL) CTO Sells $35,388.00 in Stock

CeriBell, Inc. (NASDAQ:CBLL) CTO Raymond Woo sold 1,966 shares of the firm’s stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $18.00, for a total transaction of $35,388.00. Following the transaction, the chief technology officer directly owned 195,682 shares of the company’s stock, valued at $3,522,276. This represents a 0.99% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Raymond Woo also recently made the following trade(s):

• On Friday, May 1st, Raymond Woo sold 11,104 shares of CeriBell stock. The shares were sold at an average price of $20.44, for a total transaction of $226,965.76.
• On Wednesday, April 1st, Raymond Woo sold 11,112 shares of CeriBell stock. The shares were sold at an average price of $18.56, for a total transaction of $206,238.72.
• On Monday, March 2nd, Raymond Woo sold 8,087 shares of CeriBell stock. The shares were sold at an average price of $18.25, for a total transaction of $147,587.75.

CeriBell Price Performance

Shares of NASDAQ CBLL opened at $18.67 on Friday. CeriBell, Inc. has a fifty-two week low of $10.85 and a fifty-two week high of $24.33. The company has a 50 day simple moving average of $19.07 and a two-hundred day simple moving average of $19.34. The company has a market capitalization of $708.34 million, a price-to-earnings ratio of -11.45 and a beta of 0.99. The company has a debt-to-equity ratio of 0.14, a quick ratio of 10.01 and a current ratio of 10.44.

CeriBell (NASDAQ:CBLL) last issued its earnings results on Monday, May 11th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.13). The firm had revenue of $26.49 million during the quarter, compared to the consensus estimate of $26.09 million. CeriBell had a negative return on equity of 38.19% and a negative net margin of 63.51%. Analysts expect that CeriBell, Inc. will post -1.69 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. grew its position in CeriBell by 41.4% in the 4th quarter. Russell Investments Group Ltd. now owns 2,918 shares of the company’s stock worth $64,000 after purchasing an additional 854 shares during the period. Sei Investments Co. grew its position in CeriBell by 2.3% in the 1st quarter. Sei Investments Co. now owns 50,360 shares of the company’s stock worth $923,000 after purchasing an additional 1,125 shares during the period. Caitong International Asset Management Co. Ltd grew its position in CeriBell by 3,971.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock worth $28,000 after purchasing an additional 1,231 shares during the period. Deutsche Bank AG grew its position in CeriBell by 1.7% in the 4th quarter. Deutsche Bank AG now owns 85,182 shares of the company’s stock worth $1,868,000 after purchasing an additional 1,393 shares during the period. Finally, Strs Ohio bought a new stake in CeriBell in the 1st quarter worth approximately $27,000.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. Canaccord Genuity Group dropped their target price on shares of CeriBell from $28.00 to $25.00 and set a “buy” rating on the stock in a research note on Tuesday, May 12th. Weiss Ratings upgraded shares of CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $22.20.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.